Potential drug–drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma

References

• Campagna R, Bacchetti T, Salvolini E, et al. Paraoxonase-2 silencing enhances sensitivity of A375 melanoma cells to treatment with cisplatin. Antioxidants. 2020 Dec 7;9(12):1238.
   Web of Science ®Google Scholar
• Guo YJ, Pan WW, Liu SB, et al. ERK/MAPK signalling pathway and tumorigenesis (review). Exp Ther Med. 2020 Mar;19(3):1997–2007. doi: 10.3892/etm.2020.8454
   PubMed Web of Science ®Google Scholar
• Campagna R, Salvolini E, Pompei V, et al. Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines. Pigment Cell Melanoma Res. 2021 Nov;34(6):1039–1048. doi: 10.1111/pcmr.12993
   PubMed Web of Science ®Google Scholar
• Bacchetti T, Salvolini E, Pompei V, et al. Paraoxonase-2: a potential biomarker for skin cancer aggressiveness. Eur J Clin Invest. 2021 May;51(5):e13452. doi: 10.1111/eci.13452
   PubMed Web of Science ®Google Scholar
• Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014 Jul;11(7):385–400. doi: 10.1038/nrclinonc.2014.83
   PubMed Web of Science ®Google Scholar
• Ismail RK, Suijkerbuijk KPM, de Boer A, et al. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. Melanoma Res. 2022 Dec 1;32(6):460–468.
   PubMed Web of Science ®Google Scholar
• Osrodek M, Rozanski M, Czyz M. Insulin reduces the efficacy of vemurafenib and trametinib in melanoma cells. Cancer Manag Res. 2020 Aug 13;12:7231–7250. doi: 10.2147/CMAR.S263767
   PubMed Web of Science ®Google Scholar
• Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Therapeut Adv Med Oncol. 2015;7(2):122–136. doi: 10.1177/1758834014566428
   PubMed Web of Science ®Google Scholar
• Specenier P. An overview of binimetinib for the treatment of melanoma. Expert Opin Pharmacother. 2020 May;21(7):747–754. doi: 10.1080/14656566.2020.1729122
   PubMed Web of Science ®Google Scholar
• MEKTOVI (binimetinib). Prescribing information. Boulder: Array BioPharma Inc.; 2018. [cited 2018 Sep]. Available from: https://labeling.pfizer.com/ShowLabeling.aspx?id=12988
   Google Scholar
• MEKTOVI (changed to BALIMEK) [binimetinib]. Assessment Report. London: European Medicines Agency (EMA); 2017. [Cited 2018 Sep]. Available from: https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf.
   Google Scholar
• Marques SC, Ikediobi ON. The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions. Hum Genomics. 2010 Apr;4(4):238–249. doi: 10.1186/1479-7364-4-4-238
   PubMedGoogle Scholar
• BRAFTOVI(encorafenib). Prescribing information. Boulder: Array BioPharma Inc.; 2018. [cited 2018 Sep]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf
   Google Scholar
• Dong J, Li S, Liu G. Binimetinib is a potent reversible and time-dependent inhibitor of cytochrome P450 1A2. Chem Res Toxicol. 2021 Apr 19;34(4):1169–1174.
   PubMed Web of Science ®Google Scholar
• Guo J, Zhu X, Badawy S, et al. Metabolism and mechanism of human cytochrome P450 enzyme 1A2. Curr Drug Metab. 2021;22(1):40–49. doi: 10.2174/18755453MTEyCOTgcx
   PubMed Web of Science ®Google Scholar
• Ivanyuk A, Livio F, Biollaz J, et al. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017 Aug;56(8):825–892. doi: 10.1007/s40262-017-0506-8
   PubMed Web of Science ®Google Scholar
• Andrlová H, Zeiser R, Meiss F. Cobimetinib (GDC-0973, XL518). Recent Results Cancer Res. 2018;211:177–186.
   PubMedGoogle Scholar
• COTELLIC (cobimetinib). Prescribing information. South San Francisco: Genentech, Inc.; 2015 [cited 2018 Jan]. https://www.gene.com/download/pdf/cotellicprescribing.pdf
   Google Scholar
• US Food and Drug Administration. Cobimetinib (COTELLIC) clinical pharmacology and biopharmaceutics review: summary basis of approval. Silver spring: US food and drug adminis- tration. 2015. [cited 2016 May5]. Available from: https://www.gene.com/download/pdf/cotellicprescribing.pdf
   Google Scholar
• Budha NR, Ji T, Musib L, et al. Evaluation of cytochrome P450 3A4-mediated drug-drug interaction potential for cobimetinib using physiologically based pharmacokinetic modeling and simulation. Clin Pharmacokinet. 2016 Nov;55(11):1435–1445. doi: 10.1007/s40262-016-0412-5
   PubMed Web of Science ®Google Scholar
• Choo EF, Woolsey S, DeMent K, et al. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. Drug Metab Dispos. 2015 Jun;43(6):864–869. doi: 10.1124/dmd.115.063743
   PubMed Web of Science ®Google Scholar
• Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008 May;9(4):310–322. doi: 10.2174/138920008784220664
   PubMed Web of Science ®Google Scholar
• Musib L, Choo E, Deng Y, et al. Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. Mol Pharm. 2013 Nov 4;10(11):4046–4054. doi: 10.1021/mp400383x
   PubMed Web of Science ®Google Scholar
• Lewis K, Hauschild A, Larkin J, et al. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. Eur J Cancer. 2019 Jul;116:45–55. doi: 10.1016/j.ejca.2019.05.002
   PubMed Web of Science ®Google Scholar
• Lugowska I, Koseła-Paterczyk H, Kozak K, et al. Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther. 2015 Aug 25;8:2251–2259. doi: 10.2147/OTT.S72951
   PubMed Web of Science ®Google Scholar
• Voon PJ, Chen EX, Chen HX, et al. Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. J Exp Clin Cancer Res. 2022 Feb 7;41(1):51. doi: 10.1186/s13046-021-02236-7
   PubMed Web of Science ®Google Scholar
• Mak G, Soria JC, Blagden SP, et al. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. Br J Cancer. 2019 May;120(10):975–981. doi: 10.1038/s41416-019-0452-3
   PubMed Web of Science ®Google Scholar
• MEKINIST (trametinib). Prescribing information. Zebulon: GlaxoSmithKline; 2013. [cited 2018 Sep]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204114s024lbl.pdf
   Google Scholar
• Isberner N, Gesierich A, Balakirouchenane D, et al. Monitoring of dabrafenib and trametinib in serum and self-sampled capillary blood in patients with BRAFV600-mutant melanoma. Cancers (Basel). 2022 Sep 20;14(19):4566. doi: 10.3390/cancers14194566
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Taylor D, Xu X, et al. Pharmacokinetic interaction between the MEK1/MEK2 inhibitor trametinib and oral contraceptives containing norethindrone and ethinyl estradiol in female patients with solid tumors. Clin Pharmacol Drug Dev. 2022 May;11(5):585–596. doi: 10.1002/cpdd.1052
   PubMed Web of Science ®Google Scholar
• Vaidhyanathan S, Mittapalli RK, Sarkaria JN, et al. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab Dispos. 2014 Aug;42(8):1292–1300. doi: 10.1124/dmd.114.058339
   PubMed Web of Science ®Google Scholar
• Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207–215. doi: 10.1056/NEJMoa1105358
   PubMed Web of Science ®Google Scholar
• Amir M, Somakala K, Ali S. p38 MAP kinase inhibitors as anti-inflammatory agents. Mini Rev Med Chem. 2013;13(14):2082–2096. doi: 10.2174/13895575113136660098
   PubMed Web of Science ®Google Scholar
• Ganzetti G, Sartini D, Campanati A, et al. Nicotinamide N-methyltransferase: potential involvement in cutaneous malignant melanoma. Melanoma Res. 2018 Apr;28(2):82–88. doi: 10.1097/CMR.0000000000000430
   PubMed Web of Science ®Google Scholar
• Cubero DIG, Abdalla BMZ, Schoueri J, et al. Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors. Drugs Context. 2018 Jul 17;7:212516. doi: 10.7573/dic.212516
   PubMedGoogle Scholar
• Mackin AG, Pecen PE, Dinsmore AL, et al. Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019 Oct;29(5):522–526. doi: 10.1097/CMR.0000000000000599
   PubMed Web of Science ®Google Scholar
• Heinzerling L, Eigentler TK, Fluck M, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019 May 23;4(3):e000491.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–1260. doi: 10.1016/S1470-2045(16)30122-X
   PubMed Web of Science ®Google Scholar
• Chen FW, Tseng D, Reddy S, et al. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatol. 2014 Nov;150(11):1209–1212. doi: 10.1001/jamadermatol.2014.838
   PubMed Web of Science ®Google Scholar
• Gogas HJ, Flaherty KT, Dummer R, et al. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. Eur J Cancer. 2019;119:97–106. doi: 10.1016/j.ejca.2019.07.016
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trame- tinib versus dabrafenib and placebo for Val600 BRAF-mutant mela- noma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–451. doi: 10.1016/S0140-6736(15)60898-4
   PubMed Web of Science ®Google Scholar
• Mukai K, Kamata M, Miyazaki M, et al. Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma. J Dermatol. 2021 May;48(5):707–709. doi: 10.1111/1346-8138.15813
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888. doi: 10.1056/NEJMoa1406037
   PubMed Web of Science ®Google Scholar
• Daud A, Gill J, Kamra S, et al. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol. 2017;10(1):10. doi: 10.1186/s13045-016-0369-8
   PubMedGoogle Scholar
• Banks M, Crowell K, Proctor A, et al. Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism. Cardiovasc Toxicol. 2017 Oct;17(4):487–493. doi: 10.1007/s12012-017-9425-z
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, ElHalawani H, Ahmed H. Risk of selected cardiovascular toxicities in patients with cancer treated with MEK inhibitors: a comparative systematic review and meta-analysis. J Glob Oncol. 2015 Nov 25;1(2):73–82.
   PubMedGoogle Scholar
• Mincu RI, Mahabadi AA, Michel L, et al. Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(8):e198890. doi: 10.1001/jamanetworkopen.2019.8890
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanO E, ElHalawani H, Ahmed H. Doublet BRAF/MEK inhibition versus single-agent Braf inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data. Clin Transl Oncol. 2016;18(8):848–858. doi: 10.1007/s12094-015-1438-0
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Ferrucci PF, Ribas A, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019;25(6):941–946. doi: 10.1038/s41591-019-0448-9
   PubMed Web of Science ®Google Scholar
• Kunakorntham P, Pattanaprateep O, Dejthevaporn C, et al. Detection of statin-induced rhabdomyolysis and muscular related adverse events through data mining technique. BMC Med Inform Decis Mak. 2022 Sep 5;22(1):233. doi: 10.1186/s12911-022-01978-4
   PubMed Web of Science ®Google Scholar
• Haber CJ, Meltzer SJ, Present DH, et al. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology. 1986;91(4):982–986. doi: 10.1016/0016-5085(86)90703-1
   PubMed Web of Science ®Google Scholar
• Maxson CJ, Greenfield SM, Turner JL. Acute pancreatitis as a common complication of 2’,3’-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol. 1992;87:708–13. 6
   PubMed Web of Science ®Google Scholar
• Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009 Mar;16(2):43–48. doi: 10.1155/2009/282540
   PubMed Web of Science ®Google Scholar
• Nowrouzi A, Kafiabasabadi S, Rodriguez-Calzadilla M, et al. Central retinal vein occlusion in a patient using the antipsychotic drug olanzapine: a case report. J Med Case Rep. 2021 May 29;15(1):307. doi: 10.1186/s13256-021-02865-8
   PubMedGoogle Scholar
• Taki K, Kida T, Fukumoto M, et al. Central retinal vein occlusion in 2 patients using Antipsychotic drugs. Case Rep Ophthalmol. 2017 Jul 26;8(2):410–415.
   PubMedGoogle Scholar
• Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):603–615. doi: 10.1016/S1470-2045(18)30142-6
   PubMed Web of Science ®Google Scholar
• Schuler M, Zimmer L, Kim KB, et al. Phase Ib/II trial of ribociclib in combination with binimetinib in patients with NRAS-mutant melanoma. Clin Cancer Res. 2022 Jul 15;28(14):3002–3010.
   PubMed Web of Science ®Google Scholar
• Ryabaya O, Prokofieva A, Akasov R, et al. Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells. Biomed Pharmacother. 2019 Jan;109:2548–2560.
   PubMed Web of Science ®Google Scholar
• Ryabaya OO, Abramov IS, Khochenkov DA, et al. Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro. Invest New Drugs. 2021 Aug;39(4):987–1000. doi: 10.1007/s10637-021-01089-3
   PubMed Web of Science ®Google Scholar
• Queralt B, Cuyàs E, Bosch-Barrera J, et al. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget. 2016 Dec 13;7(50):82185–82199. doi: 10.18632/oncotarget.11985
   PubMedGoogle Scholar
• Bikhezar F, de Kruijff RM, van der Meer AJGM, et al. Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma. J Neurooncol. 2020 Jan;146(2):239–246. doi: 10.1007/s11060-019-03365-y
   PubMed Web of Science ®Google Scholar
• Crassini K, Shen Y, Stevenson WS, et al. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. Br J Haematol. 2018 Aug;182(3):360–372. doi: 10.1111/bjh.15282
   PubMed Web of Science ®Google Scholar
• Rosenbaum E, Kelly C, D’Angelo SP, et al. A phase I study of binimetinib (MEK162) combined with pexidartinib (PLX3397) in patients with advanced gastrointestinal stromal tumor. Oncology. 2019 Oct;24(10):1309–e983. doi: 10.1634/theoncologist.2019-0418
   Google Scholar
• Keating GM. Cobimetinib plus vemurafenib: a review in BRAF (V600) mutation-positive unresectable or metastatic melanoma. Drugs. 2016 Apr;76(5):605–615. doi: 10.1007/s40265-016-0562-7
   PubMed Web of Science ®Google Scholar
• Liu W, Stachura P, Xu HC, et al. Repurposing the serotonin agonist tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications. J Exp Clin Cancer Res. 2020;39(1):38. doi: 10.1186/s13046-020-1539-7
   PubMed Web of Science ®Google Scholar
• Sinik L, Minson KA, Tentler JJ, et al. Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma. Mol Cancer Ther. 2019 Feb;18(2):278–288. doi: 10.1158/1535-7163.MCT-18-0456
   PubMed Web of Science ®Google Scholar
• Jiang H, Courau T, Borison J, et al. Activating immune recognition in pancreatic ductal adenocarcinoma via autophagy inhibition, MEK blockade, and CD40 agonism. Gastroenterology. 2022 Feb;162(2):590–603.e14. doi: 10.1053/j.gastro.2021.09.066
   PubMed Web of Science ®Google Scholar
• Ma L, Xu Y, Xu X. Targeted MEK inhibition by cobimetinib enhances doxorubicin’s efficacy in osteosarcoma models. Biochem Biophys Res Commun. 2020 Aug 27;529(3):622–628.
   PubMed Web of Science ®Google Scholar
• Zhang L, Xie D, Lei Y, et al. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma. Future Oncol. 2021 Aug;17(23):3051–3060. doi: 10.2217/fon-2021-0256
   PubMed Web of Science ®Google Scholar
• Shorstova T, Su J, Zhao T, et al. Reprogramming of nucleotide metabolism mediates synergy between epigenetic therapy and MAP kinase inhibition. Molecular Cancer Therapeutics. 2021 Jan;20(1):64–75. doi: 10.1158/1535-7163.MCT-20-0259
   PubMed Web of Science ®Google Scholar
• Rissmann R, Hessel MH, Cohen AF. Vemurafenib/Dabrafenib and trametinib. Br J Clin Pharmacol. 2015 Oct;80(4):765–767. doi: 10.1111/bcp.12651
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–1703. doi: 10.1056/NEJMoa1210093
   PubMed Web of Science ®Google Scholar
• Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019 Aug 15;381(7):626–636.
   PubMed Web of Science ®Google Scholar
• In brief: Dabrafenib (Tafinlar) and trametinib (Mekinist) for glioma. Med Lett Drugs Ther. 2023 Apr 17;65(16741674):e75–e76. doi: 10.58347/tml.2023.1674i
   PubMedGoogle Scholar
• Tawbi HA, Robert C, Brase JC, et al. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). J Immunother Cancer. 2022 Jun;10(6):e004226. doi: 10.1136/jitc-2021-004226
   PubMed Web of Science ®Google Scholar
• Vujic I, Sanlorenzo M, Posch C, et al. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget. 2015 Jan 20;6(2):969–978. doi: 10.18632/oncotarget.2824
   PubMedGoogle Scholar
• Close DA, Kirkwood JM, Fecek RJ, et al. Unbiased high-throughput drug combination pilot screening identifies synergistic drug combinations effective against patient-derived and drug-resistant melanoma cell lines. SLAS Discov. 2021 Jun;26(5):712–729. doi: 10.1177/2472555220970917
   PubMed Web of Science ®Google Scholar
• Liu L, Mayes PA, Eastman S, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015 Apr 1;21(7):1639–1651. doi: 10.1158/1078-0432.CCR-14-2339
   PubMed Web of Science ®Google Scholar
• Wu CE, Koay TS, Esfandiari A, et al. ATM dependent DUSP6 modulation of p53 involved in synergistic targeting of MAPK and p53 pathways with trametinib and MDM2 inhibitors in cutaneous melanoma. Cancers (Basel). 2018 Dec 20;11(1):3. doi: 10.3390/cancers11010003
   PubMed Web of Science ®Google Scholar
• Witkowski J, Polak S, Rogulski Z, et al. In vitro/in vivo translation of synergistic combination of MDM2 and MEK inhibitors in melanoma using PBPK/PD modelling: part I. Int J Mol Sci. 2022 Oct 26;23(21):12984. doi: 10.3390/ijms232112984
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Sandhu S, Lewis KD, et al. Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in metastatic melanoma; a phase 1 study. Invest New Drugs. 2022 Oct;40(5):1051–1065. doi: 10.1007/s10637-022-01253-3
   PubMed Web of Science ®Google Scholar
• Faião-Flores F, Emmons MF, Durante MA, et al. HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma. Clin Cancer Res. 2019 Sep 15;25(18):5686–5701. doi: 10.1158/1078-0432.CCR-18-3382
   PubMed Web of Science ®Google Scholar
• Falcomatà C, Bärthel S, Widholz SA, et al. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nat Cancer. 2022 Mar;3(3):318–336. doi: 10.1038/s43018-021-00326-1
   PubMedGoogle Scholar
• Bush KT, Boichard A, Tsigelny IF. In VitroElucidation of drug combination synergy in treatment of pancreatic ductal adenocarcinoma. Anticancer Res. 2018 Apr;38(4):1967–1977.
   PubMed Web of Science ®Google Scholar
• Ciuffreda L, Del Curatolo A, Falcone I, et al. Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer. Ann Oncol. 2017 Nov 1;28(11):2896–2898. doi: 10.1093/annonc/mdx335
   PubMed Web of Science ®Google Scholar
• Kan G, Wang Z, Sheng C, et al. Dual inhibition of DKC1 and MEK1/2 synergistically restrains the growth of colorectal cancer cells. Adv Sci. 2021 Mar 15;8(10):2004344.
   Web of Science ®Google Scholar
• Dilly A, Honick BD, Lee YJ, et al. Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors. Cancer Med. 2020 Mar;9(5):1753–1767. doi: 10.1002/cam4.2847
   PubMed Web of Science ®Google Scholar
• Zhou S, Xia H, Xu H, et al. ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells. J Exp Clin Cancer Res. 2018 Sep 5;37(1):218. doi: 10.1186/s13046-018-0862-8
   PubMedGoogle Scholar
• Tao Z, Le Blanc JM, Wang C, et al. Coadministration of trametinib and palbociclib radiosensitizes KRAS-Mutant non-small cell lung cancers in vitro and in vivo. Clin Cancer Res. 2016 Jan 1;22(1):122–133.
   PubMed Web of Science ®Google Scholar
• Levine BD, Cagan RL. Drosophila lung cancer models identify trametinib plus statin as candidate therapeutic. Cell Rep. 2016 Feb 16;14(6):1477–1487.
   PubMed Web of Science ®Google Scholar
• Lee JW, Zhang Y, Eoh KJ, et al. The combination of MEK inhibitor with immunomodulatory antibodies targeting programmed death 1 and programmed death ligand 1 results in prolonged survival in Kras/p53-driven lung cancer. J Thorac Oncol. 2019 Jun;14(6):1046–1060. doi: 10.1016/j.jtho.2019.02.004
   PubMed Web of Science ®Google Scholar
• Sato H, Yamamoto H, Sakaguchi M, et al. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Cancer Sci. 2018 Oct;109(10):3183–3196. doi: 10.1111/cas.13763
   PubMed Web of Science ®Google Scholar
• Sun CY, Li YZ, Cao D, et al. Rapamycin and trametinib: a rational combination for treatment of NSCLC. Int J Biol Sci. 2021 Jul 25;17(12):3211–3223. doi: 10.7150/ijbs.62752
   PubMed Web of Science ®Google Scholar
• Prasad M, Zorea J, Jagadeeshan S, et al. MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. J Immunother Cancer. 2022 Mar;10(3):e003917. doi: 10.1136/jitc-2021-003917
   PubMed Web of Science ®Google Scholar
• Yee PS, Zainal NS, Gan CP, et al. Synergistic growth inhibition by afatinib and trametinib in preclinical oral squamous cell carcinoma models. Target Oncol. 2019 Apr;14(2):223–235. doi: 10.1007/s11523-019-00626-8
   PubMed Web of Science ®Google Scholar
• Gong X, Fan L, Wang P. MEK inhibition by trametinib overcomes chemoresistance in preclinical nasopharyngeal carcinoma models. Anticancer Drugs. 2021 Oct 1;32(9):978–985.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Iglesias-Bartolomé R, Wang Z, et al. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget. 2016 Mar 8;7(10):10696–10709. doi: 10.18632/oncotarget.7372
   PubMedGoogle Scholar
• Pétigny-Lechartier C, Duboc C, Jebahi A, et al. The mTORC1/2 inhibitor AZD8055 strengthens the efficiency of the MEK inhibitor trametinib to reduce the Mcl-1/[Bim and Puma] ratio and to sensitize ovarian carcinoma cells to ABT-737. Mol Cancer Ther. 2017 Jan;16(1):102–115. doi: 10.1158/1535-7163.MCT-16-0342
   PubMed Web of Science ®Google Scholar
• Mert I, Chhina J, Allo G, et al. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. Gynecol Oncol. 2017 Aug;146(2):319–326. doi: 10.1016/j.ygyno.2017.05.019
   PubMed Web of Science ®Google Scholar
• Leung EY, Kim JE, Askarian-Amiri M, et al. Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines. PLoS One. 2014 Aug 29;9(8):e105792.
   PubMed Web of Science ®Google Scholar
• Mizukami T, Togashi Y, Sogabe S, et al. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. Int J Oncol. 2015 Aug;47(2):499–505. doi: 10.3892/ijo.2015.3050
   PubMed Web of Science ®Google Scholar
• Wabitsch S, Tandon M, Ruf B, et al. Anti-PD-1 in combination with trametinib suppresses tumor growth and improves survival of intrahepatic cholangiocarcinoma in Mice. Cell Mol Gastroenterol Hepatol. 2021;12(3):1166–1178. doi: 10.1016/j.jcmgh.2021.05.011
   PubMed Web of Science ®Google Scholar
• Hou W, Xia H, Zhou S, et al. The MEK inhibitors enhance the efficacy of sorafenib against hepatocellular carcinoma cells through reducing p-ERK rebound. Transl Cancer Res. 2019 Aug;8(4):1224–1232. doi: 10.21037/tcr.2019.07.11
   PubMed Web of Science ®Google Scholar
• Chen SL, Hu F, Wang DW, et al. Prognosis and regulation of an adenylyl cyclase network in acute myeloid leukemia. Aging. 2020 Jun 22;12(12):11864–11877.
   PubMedGoogle Scholar
• Morales ML, Arenas A, Ortiz-Ruiz A, et al. MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. Sci Rep. 2019 Dec 9;9(1):18630. doi: 10.1038/s41598-019-54901-9
   PubMed Web of Science ®Google Scholar
• Sriskandarajah P, De Haven Brandon A, MacLeod K, et al. Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma. BMC Cancer. 2020 Mar 30;20(1):269. doi: 10.1186/s12885-020-06735-2
   PubMed Web of Science ®Google Scholar
• Anderson JL, Park A, Akiyama R, et al. Evaluation of in vitro activity of the class I PI3K inhibitor buparlisib (BKM120) in pediatric bone and soft tissue sarcomas. PLoS One. 2015 Sep 24;10(9):e0133610.
   PubMed Web of Science ®Google Scholar
• Takemoto M, Tanaka T, Tsuji R, et al. The synergistic antitumor effect of combination therapy with a MEK inhibitor and YAP inhibitor on pERK-positive neuroblastoma. Biochem Biophys Res Commun. 2021 Sep 17;570:41–46.
   PubMed Web of Science ®Google Scholar
• Bridgeman VL, Wan E, Foo S, et al. Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma. Mol Cancer Ther. 2016 Jan;15(1):172–183. doi: 10.1158/1535-7163.MCT-15-0170
   PubMed Web of Science ®Google Scholar
• Ganzetti G, Rubini C, Campanati A, et al. IL-17,IL-23, and p73 expression in cutaneous melanoma: a pilot study. Melanoma Res. 2015 Jun;25(3):232–238. doi: 10.1097/CMR.0000000000000151
   PubMed Web of Science ®Google Scholar
• Campagna R, Pozzi V, Sartini D, et al. Beyond Nicotinamide metabolism: potential role of Nicotinamide N-methyltransferase as a biomarker in skin cancers. Cancers (Basel). 2021 Sep 30;13(19):4943.
   PubMed Web of Science ®Google Scholar
• Kun E, Tsang YTM, Ng CW, et al. MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treat Rev. 2021 Jan;92:102137.
   PubMed Web of Science ®Google Scholar
• Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res. 2014 Apr 1;20(7):1965–1977. doi: 10.1158/1078-0432.CCR-13-3122
   PubMed Web of Science ®Google Scholar